Stabilized Omicron Trimeric Spike ProteinIn development. Produced in CHO cells, available soon in mg to grams.
The SARS-CoV-2 Omicron variant became known to the general public recently (end of November 2021) and is characterized by many mutations in the Spike protein and other regions of the virus genome. It seems to spread even more rapidly than the Delta variant, and questions about the protection against this variant by presently used vaccines have been raised. This variant may have an increased capacity to re-infect vaccinated people.
This product is intended for research use only.
|Stabilized Omicron Trimeric Spike Protein (in development)|
|Sequence modifications||C-terminal Transmembrane region replaced with a trimerization domain and a polyhistidine tag. Two stabilizing proline mutations. Scrambled S1/S2 furin cleavage site. D614G amino acid change.|
|Isolate (Seq ID)||–|
|Expression system||CHOExpress® cells|
|Purity||Not yet determined|
|Buffer||0.01M PBS, pH 7.4, no preservatives|